Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
February 21 2025 - 2:30AM
Abivax to Host Key Opinion Leader (KOL)
Webcast on March 17, 2025
Event to Feature Renowned Gastroenterologist Dr.
David Rubin, Highlighting the Ulcerative Colitis Treatment
Landscape and Abivax’s Pivotal ABTECT Phase 3 Trial
PARIS, France – February 21, 2025 – 8:30
AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX /
Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage
biotechnology company focused on developing innovative therapies
for chronic inflammatory diseases, today announced it will host a
Key Opinion Leader (KOL) Investor Webcast on Monday, March 17,
2025, at 9:00 a.m. EDT (2:00 p.m. CET).
The webcast will feature Professor David T.
Rubin, MD, Chief of the Section of Gastroenterology, Hepatology,
and Nutrition and Director of the Inflammatory Bowel Disease Center
at The University of Chicago. Dr. Rubin will provide expert
insights into the evolving treatment landscape for ulcerative
colitis (UC) and discuss expectations for Abivax’s ABTECT Phase 3
trial evaluating obefazimod in adults with moderately to severely
active UC. He will also explore obefazimod’s potential to address
critical unmet medical needs in UC treatment.
Following the presentation, attendees will have
the opportunity to participate in a live Q&A session with Dr.
Rubin and Abivax’s management team.
Event Details:
Date: Monday, March 17,
2025
Time: 9:00 a.m. EDT | 2:00 p.m.
CET
Format: Virtual webcast
Registration Details:
To register for the webcast and access further
event details, please click on this link
https://lifescievents.com/event/abivax-3/.
About Abivax Abivax is a
clinical-stage biotechnology company focused on developing
therapeutics that harness the body’s natural regulatory mechanisms
to stabilize the immune response in patients with chronic
inflammatory diseases. Based in France and the United States,
Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3
clinical trials for the treatment of moderately to severely active
ulcerative colitis. More information on the Company is available at
www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter,
@ABIVAX.
Contact:
Patrick MalloySVP, Investor Relations Abivax
SApatrick.malloy@abivax.com+1 847 987 4878
Abivax (NASDAQ:ABVX)
Historical Stock Chart
From Jan 2025 to Feb 2025
Abivax (NASDAQ:ABVX)
Historical Stock Chart
From Feb 2024 to Feb 2025
